-- マウンテン・プロヴィンス・ダイアモンズ(MPVD.TO)は、タームローンの満期日と運転資金枠の元本返済日を延長したと、金曜日に発表した。 デューンブリッジ・ワールドワイドとの第4次修正契約に基づき、4,000万米ドルのタームローンの満期日と3,300万米ドルの運転資金枠の元本返済日が、4月30日から6月30日に変更された。 また、マウンテン・プロヴィンスは、ノースウエスト準州のガチョ・クエ鉱山におけるダイヤモンドの保有権益を83万3,000米ドルで売却し、99万9,999米ドルの売却益を得た。 これらの資金は、マウンテン・プロヴィンスが戦略的選択肢を検討する間、当面の事業継続に必要な運転資金となる。 また、マウンテン・プロヴィンスは木曜夜に、第1四半期のダイヤモンド生産量が前年同期比で増加したと発表した。 同社は200万カラットのダイヤモンドを回収し、前年同期の76万2978カラットから163%増加しました。 第1四半期の売上高は85万8173カラット、金額にして4000万カナダドル、1カラットあたり平均47カナダドルでした。前年同期の売上高は42万6268カラット、金額にして4400万カナダドル、1カラットあたり平均103カナダドルでした。 「ダイヤモンド市場は、米国の関税問題や中東情勢の不安定さなど、地政学的な不確実性によって引き続き悪影響を受けています」と、社長兼最高経営責任者(CEO)のジョナサン・コマーフォード氏は述べています。 「既にご報告した通り、当社はすべてのステークホルダーと建設的な対話を続け、市場にとって特に困難な時期を乗り切るべく取り組んでいます。現在、回収カラット数という点では非常に好調な業績を上げていますが、こうした状況が業績を覆い隠してしまっています」と、コマーフォード氏は述べています。 一方、ジェフ・スウィノガ氏は、他の複数の役員職を兼任しているため、取締役を辞任した。
Related Articles
Research Alert: CFRA Retains Hold View On Shares Of Incyte Corporation
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After Q1 earnings, we keep our target at $102, 11.8x our projected 2027 EPS forecast, below its five-year historical forward P/E average of 17.0x. We adjust our 2026 EPS estimate to $7.83 from $7.94 and our 2027 EPS view to $8.64 from $8.36. INCY reported a solid start to 2026, beating expectations on both revenue and earnings, led by robust, double-digit growth across its commercial portfolio. We think the company is going through a strategic transition beyond its cornerstone product, Jakafi, toward a diversified portfolio in hematology, oncology, and immunology, supported by a maturing late-stage pipeline and key management appointments. INCY announced the appointments of Suketu Upadhyay (the current CFO of ZBH) as its new CFO, effective May 4, and a new Head of U.S. Commercial, Mohamed Issa. While we see some execution risks ahead, we believe INCY could be at an inflection point with four new product launches in the next year and the advancement of the 10 Phase 3 studies while filling key leadership roles.
GSK's Linerixibat Gets UK Nod for Itch Linked to Biliary Disease
GSK's (GSK) Linerixibat, to be marketed as Lynavoy, has been approved by the UK's Medicines and Healthcare products Regulatory Agency for the treatment of itching in adults with primary biliary cholangitis, the agency said Friday.The oral therapy aims to reduce bile acid buildup linked to the rare liver disease, which can cause persistent itching, the agency said.The approval was supported by phase 3 data showing Linerixibat significantly reduced itching and improved sleep disruption compared with placebo, it added.Shares of GSK were down 1.2% in Friday trading.Price: $52.01, Change: $-0.30, Percent Change: -0.57%
ISM US Manufacturing Index Indicates Steady Expansion in April
The Institute for Supply Management's US manufacturing index was unchanged in April from the 52.7 reading in March, below the expectations for a 53.2 reading in a survey compiled by Bloomberg as of 7:40 am ET.There were gains in the readings for new orders and prices, but declines in production, employment and order backlogs.Other regional manufacturing sector readings have been generally positive, with exception of the Dallas and Chicago regions.The monthly national manufacturing reading from the Institute for Supply Management is reported as a headline index, with readings above 50 indicating expansion and those below 50 indicating contraction. Component indexes measure new orders, production, employment, and prices.An increase in the index further above 50 is considered a sign of a strong US manufacturing sector, generally a positive for manufacturing industry stocks. However, if that strength comes with rising input prices due to shortages, that could be a negative for stocks as well as bonds.